Has the French Biotech Industry valuation changed over the past few years?

Investors are pessimistic on the industry, indicating that they anticipate long-term growth rates will be lower than they have historically. The industry's 3-year average PS ratio 6.9x is higher than the industry's current PS ratio of 4.7x.

How does French Biotech compare with similar industries?

There is insufficient data on the sub-industries of this industry.

French (CAC) Biotech Industry Analysis

Date	Market Cap	Revenue	Earnings	PE
Sun, 26 Jun 2022	€4.7b	€993.1m	-€693,029,894.00	126x
Tue, 24 May 2022	€4.6b	€990.3m	-€689,689,666.00	136.6x
Thu, 21 Apr 2022	€5.0b	€1.2b	-€488,793,426.00	2.9x
Sat, 19 Mar 2022	€5.5b	€950.2m	-€648,336,889.00	17.7x
Mon, 14 Feb 2022	€5.4b	€929.8m	-€675,308,815.00	3x
Wed, 12 Jan 2022	€6.3b	€931.7m	-€677,895,067.00	3.2x
Fri, 10 Dec 2021	€6.9b	€923.8m	-€681,836,418.00	2.8x
Sun, 07 Nov 2021	€6.6b	€923.9m	-€679,362,761.00	2.3x
Tue, 05 Oct 2021	€6.7b	€902.9m	-€737,996,556.00	2.7x
Thu, 02 Sep 2021	€7.8b	€899.6m	-€600,532,159.12	2.9x
Sat, 31 Jul 2021	€6.6b	€899.6m	-€600,532,159.12	2.6x
Tue, 04 May 2021	€7.2b	€882.0m	-€570,006,611.92	3.1x
Fri, 05 Feb 2021	€7.1b	€911.8m	-€514,619,691.42	22.3x
Mon, 09 Nov 2020	€4.7b	€737.3m	-€578,081,678.94	8.7x
Sun, 02 Aug 2020	€4.1b	€624.3m	-€569,407,653.44	29.7x
Wed, 06 May 2020	€5.0b	€608.4m	-€585,561,414.96	18.8x
Sat, 08 Feb 2020	€4.4b	€548.6m	-€625,688,103.67	16.8x
Fri, 01 Nov 2019	€3.4b	€544.8m	-€607,268,613.10	56.4x
Mon, 05 Aug 2019	€4.3b	€547.0m	-€661,534,274.60	38.9x


FR Market	3.63%
Healthcare	6.69%
Biotech	15.95%
Biotech	15.95%

Company	Last Price	7D	1Y	Valuation
VLA Valneva	€12.65	59.4% +€507.9m	17.6%	PS3.9x
DBV DBV Technologies	€4.48	10.5% +€39.8m	-53.2%	PS83.4x
ALCLS Cellectis	€2.82	15.7% +€19.6m	-78.2%	PS3.7x
ALERS Eurobio Scientific Société anonyme	€20.04	8.9% +€17.7m	7.2%	PS3.6x
ABVX ABIVAX Société Anonyme	€11.30	6.8% +€12.1m	-64.4%	PB5.3x

Jun 03

MaaT Pharma Confirms Positive Results from Completed Phase 1b CIMON Study Evaluating MaaT033 in Blood Cancer Patients

MaaT Pharma announced completion of its Phase 1b CIMON trial evaluating the safety and tolerability of MaaT033, the Company’s high-richness, high-diversity MET for oral administration, in patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (HRMS) having received intensive chemotherapy. In this study, performed in an immuno-compromised patient population, MaaT033 presented a good safety and tolerability profile, evaluated as the primary endpoint. The topline results also show rapid and persistent engraftment of MaaT033 in the patients’ gut. The study data support the Company’s preparation to initiate a Phase 2/3 trial later this year to evaluate MaaT033’s ability to improve survival and prevent complications after allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with blood cancers. Every year, approximately 22,000 patients require allo-HSCT in the seven major markets. MaaT033’s oral formulation is designed to support long-term, ambulatory use, opening up new potential development opportunities for the Company. Today’s announcement confirms previously-announced promising interim results of the trial, which allowed early completion of the study. MaaT033 is designed to restore and maintain a healthy gut microbiome in patients with severe dysbiosis as a result of intensive chemotherapy and antibiotic treatment. Developed as an oral formulation in lyophilized capsules, its proprietary targeted-delivery design is conceived to optimize the product’s engraftment in the patient’s gut and its interaction with the immune system. Thanks to its high bacterial richness and Butycore™4 content, the product aims to reorient the gut microbial network towards immune homeostasis and restore the microbiome’s intestinal barrier function against infections. The CIMON Phase 1b trial (NCT04150393) was an open-label, dose-ranging study investigating the maximum tolerated dose of MaaT033 in patients with acute myeloid leukemia or high-risk myelodysplastic syndrome who have undergone intensive chemotherapy. The trial enrolled 21 patients in four dose escalation cohorts (up to three capsules a day for 14 days) across six sites in France. The trial allowed to select the recommended dose for MaaT033, which remains confidential at this stage. MaaT033 showed rapid and persistent engraftment with the detection of more than 60% of the MaaT033 microbial communities (OTUs5) in the patient’s gut post-exposure at the selected dose. Substantial engraftment was maintained during the treatment period and for at least three weeks after the end of treatment (last measure). Good tolerability of the candidate was also observed in this immunocompromised population, with only four serious adverse events (SAE) considered as unrelated to the treatment and one possibly related SAE (an infectious diarrhea event with no detection of the causal pathogen in the administered MaaT033 and patient recovery within four days). This is in line with the expected AE profile with standard of care treatments in this fragile population. MaaT Pharma has performed a Scientific Advice procedure with the European Medicine Agency and will move forward with preparations for a Phase 2/3 randomized, double-blind, placebo-controlled study in 340 patients, that will assess safety and tolerability of MaaT033 before and after allo-HSCT, as well as the efficacy of the candidate in improving overall survival and prevention of allo-HSCT complications. The trial initiation is planned by end of 2022. This is in line with the program announced during the Company’s IPO in November 2021, and part of the funding raised during the IPO is allocated to the clinical development of MaaT033.

French (CAC) Biotech Industry Analysis

Industry Valuation and Performance

Industry Comparison

Top Stock Gainers and Losers

Latest News

VLA

Valneva Announces Initiation of the Phase 3 Study of Lyme Disease Vaccine

ALERS

Eurobio Scientific Launches 2 New Proprietary Tests for the Diagnosis of New Variants of Sars-Cov-2 and Monkeypox

ALBPS

Biophytis Presents Preclinical Efficacy Data for Sarconeos (BIO101) in Spinal Muscular Atrophy (SMA), A Rare Neuromuscular Disease

IVA

Despite Lacking Profits Inventiva (EPA:IVA) Seems To Be On Top Of Its Debt

DBV

DBV Technologies S.A. announced that it has received €82.00136 million in funding from Vivo Capital, LLC, RA Capital Management, L.P., VR Adviser, LLC, Baker Bros. Advisors LP, Braidwell LP, Fairmount Funds Management LLC

NANO

NANOBIOTIX Announces the Reporting of New Data at the 2022 Annual Meeting of the American Society for Clinical Oncology

ALSEN

Sensorion Announces Approval in France to Initiate Proof of Concept Clinical Trial of SENS-401 for Residual Hearing Preservation During Cochlear Implantation

ABVX

Is ABIVAX Société Anonyme (EPA:ABVX) Using Too Much Debt?

IPH

Innate Pharma Announces IPH5201 Phase 2 Study in Lung Cancer

MAAT

MaaT Pharma Confirms Positive Results from Completed Phase 1b CIMON Study Evaluating MaaT033 in Blood Cancer Patients

POXEL

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

ALCLS

Cellectis S.A., Annual General Meeting, Jun 28, 2022

ALNOV

Novacyt S.A., Annual General Meeting, Jun 21, 2022

GNRO

Geneuro Is Granted Authorization by the Swiss Health Authority to Initiate A Phase II Study Evaluating Temelimab in Patients with Severe Neuropsychiatric Post-Covid Syndromes

ALQGC

Quantum Genomics Announces the End of Patient Recruitment for its Phase III Pivotal Study FRESH

ABNX

Price target increased to €4.30